摘要
人乳头瘤病毒(HPV)感染已成为头颈部鳞状细胞癌(HNSCC)的主要致病因素之一,与HPV阴性相比,HPV阳性HNSCC表现出以程序性死亡受体(PD)为代表的多种免疫细胞及其效应分子的表达增加。PD-1/PD-L1高表达的患者与HPV阳性HNSCC患者存活率的显著提高相关。而HPV阳性HNSCC患者在接受抗PD-1/程序性死亡配体(PD-L1)免疫治疗后的客观缓解率、无进展生存期、总生存期等指标较HPV阴性HNSCC患者有所提高,提示HPV阳性HNSCC患者在接受抗PD-1/PD-L1免疫治疗上可能取得更好疗效。另外,PD-1/PD-L1抑制剂联合HPV癌症疫苗、双通路抑制剂等免疫治疗方案在HPV相关癌症中已发挥出独特的优势。根据HPV状态为患者制定个体化免疫治疗是一种有前景的治疗策略。
Human papillomavirus(HPV)infection has become one of the main pathogenic factors of head and neck squamous cell carcinoma(HNSCC).The expression levels of various immune cells and effector molecules,including programmed death(PD)-1 and programmed death-ligand 1,are higher in HPV-positive HNSCC samples than in HPV-negative samples.Furthermore,patients with HPV-positive HNSCC and high PD-1 or PD-L1 expression showed significantly improved survival.Moreover,patients with HPV-positive HNSCC and on anti-PD-1/PD-L1 immunotherapy showed higher objective remission rate(ORR),progression-free survival(PFS),overall survival(OS)and other indicators than patients with HPV-negative HNSCCs,suggesting that the former received greater clinical benefits than the latter.In addition,HPV cancer vaccine combined with PD-1/PD-L1 inhibitors,dual pathway inhibitors and other immunotherapy regimens play distinct beneficial roles in HPV-related cancer.Therefore,tailoring immunotherapy to patients based on HPV status is a promising treatment strategy.
作者
刘世一
陈中
张素欣
Liu Shiyi;Chen Zhong;Zhang Suxin(Dept.of Stomatology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)
出处
《国际口腔医学杂志》
CAS
CSCD
北大核心
2024年第1期21-27,共7页
International Journal of Stomatology
基金
河北省卫生健康委员会老年病防治项目(13000022PO0860-410186E)
河北省医学科学研究课题计划(20190695)。
关键词
头颈部鳞状细胞癌
人乳头瘤病毒
程序性死亡受体/配体
免疫治疗
head and neck squamous cell carcinoma
human papillomavirus
programmed death-1/programmed death-ligand 1
immunotherapy
